EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dysregulated complement activation in COVID-19: the role of soluble complement inhibitors

Stef van der Meulen iD, Haiyu Wang iD, Saskia Nugteren iD, Frederique Ponchel iD, Anna H E Roukens iD, Cilia R Pothast iD, Mirjam H M Heemskerk iD, Kyra A Gelderman iD, Jeroen C J Eikenboom iD, Bernard M van den Berg iD, Wendy Stam iD, Coert Margadant iD und 4 weitere

Clinical and Experimental Immunology · 06.01.2026 · 220 (1)

DOI: 10.1093/cei/uxag064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 16.10.2026. Verfasst von Stef van der Meulen und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: COVID-19, Complement Activation, SARS-CoV-2. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In viral infections, complement activation can contribute to viral clearance, but excessive activation, as observed in severe coronavirus disease 2019 (COVID-19), may drive immunopathology. While much is known about complement-activating factors in COVID-19, insight into the role of endogenous complement inhibitors remains limited. We performed a longitudinal analysis within the BEAT-COVID cohort, comprising hospitalized patients with severe acute respiratory syndrome coronavirus 2 infection admitted to the intensive care unit (ICU) or ward, and age-matched healthy controls. Serum levels of the complement activation marker soluble membrane attack complex (sC5b-9) and soluble inhibitors C1-inhibitor, C4b-binding protein (C4BP), factor H, and factor I were measured by enzyme-linked immunosorbent assay. In vitro endothelial complement sensitivity was assessed by flow cytometry. Soluble inhibitors were also measured in a cohort of patients with long COVID. Patients admitted to the ICU showed elevated sC5b-9 levels compared to patients admitted to the ward and controls, correlating with disease severity, length of hospitalization, and need for mechanical ventilation, but not mortality. Unexpectedly, levels of all soluble complement inhibitors were elevated, particularly in patients admitted to the ICU. Factor H levels positively correlated with sC5b-9. Endothelial cells pre-incubated with serum from patients admitted to the ICU became more susceptible to complement attack. In patients with long COVID, factor H and C4b-binding protein levels remained elevated compared to pre-pandemic healthy controls. Severe COVID-19 is characterized by extensive complement activation despite elevated circulating inhibitor levels, suggesting impaired local complement regulation at the cell surface, potentially amplified by overwhelming systemic activation, rather than inhibitor deficiency.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Complement ActivationSARS-CoV-2HumansComplement Membrane Attack ComplexMaleFemaleComplement Factor HMiddle AgedComplement C4b-Binding ProteinAgedComplement C1 Inhibitor ProteinComplement Factor ILongitudinal Studies

Stichwörter der Autor:innen

COVID-19complement activationsoluble complement inhibitors

Substanzen

Complement Membrane Attack ComplexComplement Factor HSC5b-9 protein complexComplement C4b-Binding ProteinComplement C1 Inhibitor ProteinC4BPA protein, humanComplement Factor ICFH protein, human

Autor:innen und Institutionen

  • Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
  • Département de Rhumatologie, Université Jean Monnet Saint-Etienne, CHU Saint-Etienne, INSERM, Mines Saint-Etienne, SAINBIOSE U1059, Saint-Etienne, France.
  • Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
  • Laboratory Medical Immunology, Department of Immunology, Erasmus Medical Center, Rotterdam, The Netherlands.

ORCID-Profile: Stef van der Meulen, Haiyu Wang, Saskia Nugteren, Frederique Ponchel, Anna H E Roukens, Cilia R Pothast, Mirjam H M Heemskerk, Kyra A Gelderman, Jeroen C J Eikenboom, Bernard M van den Berg, Wendy Stam, Coert Margadant, Simone A Joosten, Leendert A Trouw

Zitieren

APA

van der Meulen, S., Wang, H., Nugteren, S., Ponchel, F., Roukens, A. H. E., Pothast, C. R., Heemskerk, M. H. M., Gelderman, K. A., Eikenboom, J. C. J., van den Berg, B. M., Stam, W., Margadant, C., Joosten, S. A., Trouw, L. A., BEAT-COVID study group, & the (2026). Dysregulated complement activation in COVID-19: the role of soluble complement inhibitors. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag064

Vancouver

van der Meulen S, Wang H, Nugteren S, Ponchel F, Roukens AHE, Pothast CR, et al. Dysregulated complement activation in COVID-19: the role of soluble complement inhibitors. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag064

BibTeX
@article{vanderMeulen2026,
  author = {van der Meulen, Stef and Wang, Haiyu and Nugteren, Saskia and Ponchel, Frederique and Roukens, Anna H E and Pothast, Cilia R and Heemskerk, Mirjam H M and Gelderman, Kyra A and Eikenboom, Jeroen C J and van den Berg, Bernard M and Stam, Wendy and Margadant, Coert and Joosten, Simone A and Trouw, Leendert A and BEAT-COVID study group, BEAT-COVID study group and the, the},
  title = {Dysregulated complement activation in COVID-19: the role of soluble complement inhibitors},
  journal = {Clinical and Experimental Immunology},
  year = {2026},
  volume = {220},
  number = {1},
  doi = {10.1093/cei/uxag064}
}
Kostenlos starten →